TNFα-based isolated Hyperthermic Limb Perfusion (HILP) in the treatment of limb recurrent melanoma

Update 16 years after its first clinical application

Franco Di Filippo, F. Cavaliere, R. Garinei, M. Anzà, P. Di Angelo, A. Psaila, L. Piarulli, A. Callopoli, P. Bruno, S. Di Filippo, F. Priore

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hyperthermic Limb Perfusion (HILP) with Tumor Necrosis Factor alpha (TNFα) and interferon gamma (IFNγ) was pioneered by Lienard and Lejeune in 1988. TNFα was empirically employed at a dosage of 3-4 mg that is ten times the systemic maximum tolerated dose (MTD). Sixteen years after its first clinical application more than 300 patients have been treated and some clarifications can be made regarding three major questions: the real role of IFNγ, the TNFα dose and eligibility criteria for patient selection. A randomised phase II study has demonstrated that IFNγ does not increase significantly the efficacy but does increase side-effects. Experimental and clinical results seem to indicate that patients with bulky melanoma disease can really benefit from TNFα HILP carried out with only 1 mg.

Original languageEnglish
Pages (from-to)62-65
Number of pages4
JournalJournal of Chemotherapy
Volume16
Issue numberSUPPL. 5
Publication statusPublished - Nov 2004

Fingerprint

Melanoma
Extremities
Tumor Necrosis Factor-alpha
Perfusion
Interferon-gamma
Maximum Tolerated Dose
Therapeutics
Interferon-alpha
Patient Selection

Keywords

  • HILP
  • Melanoma
  • TNF

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Di Filippo, F., Cavaliere, F., Garinei, R., Anzà, M., Di Angelo, P., Psaila, A., ... Priore, F. (2004). TNFα-based isolated Hyperthermic Limb Perfusion (HILP) in the treatment of limb recurrent melanoma: Update 16 years after its first clinical application. Journal of Chemotherapy, 16(SUPPL. 5), 62-65.

TNFα-based isolated Hyperthermic Limb Perfusion (HILP) in the treatment of limb recurrent melanoma : Update 16 years after its first clinical application. / Di Filippo, Franco; Cavaliere, F.; Garinei, R.; Anzà, M.; Di Angelo, P.; Psaila, A.; Piarulli, L.; Callopoli, A.; Bruno, P.; Di Filippo, S.; Priore, F.

In: Journal of Chemotherapy, Vol. 16, No. SUPPL. 5, 11.2004, p. 62-65.

Research output: Contribution to journalArticle

Di Filippo, F, Cavaliere, F, Garinei, R, Anzà, M, Di Angelo, P, Psaila, A, Piarulli, L, Callopoli, A, Bruno, P, Di Filippo, S & Priore, F 2004, 'TNFα-based isolated Hyperthermic Limb Perfusion (HILP) in the treatment of limb recurrent melanoma: Update 16 years after its first clinical application', Journal of Chemotherapy, vol. 16, no. SUPPL. 5, pp. 62-65.
Di Filippo, Franco ; Cavaliere, F. ; Garinei, R. ; Anzà, M. ; Di Angelo, P. ; Psaila, A. ; Piarulli, L. ; Callopoli, A. ; Bruno, P. ; Di Filippo, S. ; Priore, F. / TNFα-based isolated Hyperthermic Limb Perfusion (HILP) in the treatment of limb recurrent melanoma : Update 16 years after its first clinical application. In: Journal of Chemotherapy. 2004 ; Vol. 16, No. SUPPL. 5. pp. 62-65.
@article{bba99de8a5ed4a1abeed373da4d839ef,
title = "TNFα-based isolated Hyperthermic Limb Perfusion (HILP) in the treatment of limb recurrent melanoma: Update 16 years after its first clinical application",
abstract = "Hyperthermic Limb Perfusion (HILP) with Tumor Necrosis Factor alpha (TNFα) and interferon gamma (IFNγ) was pioneered by Lienard and Lejeune in 1988. TNFα was empirically employed at a dosage of 3-4 mg that is ten times the systemic maximum tolerated dose (MTD). Sixteen years after its first clinical application more than 300 patients have been treated and some clarifications can be made regarding three major questions: the real role of IFNγ, the TNFα dose and eligibility criteria for patient selection. A randomised phase II study has demonstrated that IFNγ does not increase significantly the efficacy but does increase side-effects. Experimental and clinical results seem to indicate that patients with bulky melanoma disease can really benefit from TNFα HILP carried out with only 1 mg.",
keywords = "HILP, Melanoma, TNF",
author = "{Di Filippo}, Franco and F. Cavaliere and R. Garinei and M. Anz{\`a} and {Di Angelo}, P. and A. Psaila and L. Piarulli and A. Callopoli and P. Bruno and {Di Filippo}, S. and F. Priore",
year = "2004",
month = "11",
language = "English",
volume = "16",
pages = "62--65",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "SUPPL. 5",

}

TY - JOUR

T1 - TNFα-based isolated Hyperthermic Limb Perfusion (HILP) in the treatment of limb recurrent melanoma

T2 - Update 16 years after its first clinical application

AU - Di Filippo, Franco

AU - Cavaliere, F.

AU - Garinei, R.

AU - Anzà, M.

AU - Di Angelo, P.

AU - Psaila, A.

AU - Piarulli, L.

AU - Callopoli, A.

AU - Bruno, P.

AU - Di Filippo, S.

AU - Priore, F.

PY - 2004/11

Y1 - 2004/11

N2 - Hyperthermic Limb Perfusion (HILP) with Tumor Necrosis Factor alpha (TNFα) and interferon gamma (IFNγ) was pioneered by Lienard and Lejeune in 1988. TNFα was empirically employed at a dosage of 3-4 mg that is ten times the systemic maximum tolerated dose (MTD). Sixteen years after its first clinical application more than 300 patients have been treated and some clarifications can be made regarding three major questions: the real role of IFNγ, the TNFα dose and eligibility criteria for patient selection. A randomised phase II study has demonstrated that IFNγ does not increase significantly the efficacy but does increase side-effects. Experimental and clinical results seem to indicate that patients with bulky melanoma disease can really benefit from TNFα HILP carried out with only 1 mg.

AB - Hyperthermic Limb Perfusion (HILP) with Tumor Necrosis Factor alpha (TNFα) and interferon gamma (IFNγ) was pioneered by Lienard and Lejeune in 1988. TNFα was empirically employed at a dosage of 3-4 mg that is ten times the systemic maximum tolerated dose (MTD). Sixteen years after its first clinical application more than 300 patients have been treated and some clarifications can be made regarding three major questions: the real role of IFNγ, the TNFα dose and eligibility criteria for patient selection. A randomised phase II study has demonstrated that IFNγ does not increase significantly the efficacy but does increase side-effects. Experimental and clinical results seem to indicate that patients with bulky melanoma disease can really benefit from TNFα HILP carried out with only 1 mg.

KW - HILP

KW - Melanoma

KW - TNF

UR - http://www.scopus.com/inward/record.url?scp=11144240982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144240982&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 62

EP - 65

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - SUPPL. 5

ER -